Treatment for Metastatic Melanoma
For metastatic melanoma, BRAF mutation testing is mandatory upfront, and first-line treatment depends on BRAF status: BRAF wild-type patients should receive immunotherapy (nivolumab plus ipilimumab, nivolumab plus relatlimab, nivolumab alone, or pembrolizumab), while BRAF V600-mutant patients can receive either immunotherapy or targeted therapy (dabrafenib plus trametinib, encorafenib plus binimetinib, or vemurafenib plus cobimetinib), with immunotherapy generally preferred in the absence of high tumor burden or symptomatic disease. 1
BRAF Mutation Testing
- All patients with unresectable or metastatic cutaneous melanoma require BRAF V600 mutation testing to guide treatment selection 1
- Testing should be performed immediately upon diagnosis of metastatic disease, as it determines eligibility for targeted therapy options 1
First-Line Treatment by BRAF Status
BRAF Wild-Type Melanoma
Immunotherapy is the only option for BRAF wild-type disease. The following regimens are recommended with no specific order of preference 1:
- Nivolumab plus ipilimumab followed by nivolumab maintenance
- Nivolumab plus relatlimab
- Nivolumab monotherapy
- Pembrolizumab monotherapy
The combination of nivolumab plus ipilimumab offers the highest response rates but carries significantly greater toxicity risk compared to single-agent PD-1 inhibitors 1
BRAF V600-Mutant Melanoma
Both immunotherapy and targeted therapy are options, creating a critical decision point. First-line options include 1:
Immunotherapy options (same as BRAF wild-type):
- Nivolumab plus ipilimumab followed by nivolumab
- Nivolumab plus relatlimab
- Nivolumab monotherapy
- Pembrolizumab monotherapy
Targeted therapy combinations:
- Dabrafenib plus trametinib
- Encorafenib plus binimetinib
- Vemurafenib plus cobimetinib
Clinical Decision Algorithm for BRAF-Mutant Disease
When choosing between immunotherapy and targeted therapy for BRAF-mutant melanoma, use the following approach:
Favor Immunotherapy First When:
- Low tumor burden with asymptomatic disease 2, 3
- Normal or mildly elevated LDH levels 2
- Absence of symptomatic visceral metastases 2
- No prior adjuvant systemic therapy (real-world data suggest better survival with immunotherapy first-line in this setting) 3
- Patient can tolerate potential delayed response and immune-related adverse events 2
Favor Targeted Therapy First When:
- High tumor burden requiring rapid disease control 2, 3
- Significantly elevated LDH levels 2
- Symptomatic visceral metastases (liver, lung) requiring urgent response 4, 2
- Rapidly progressive disease 2
- Symptomatic brain metastases (though both modalities have activity) 2
- Patient cannot tolerate immunotherapy toxicity or has contraindications 2
Key consideration: Targeted therapy produces rapid responses (often within weeks) but may lack the durability of immunotherapy, while immunotherapy offers potential for long-term survival but with delayed onset of response 5, 2, 3
Second-Line Treatment After Progression
After Anti-PD-1 Therapy Failure
For BRAF wild-type patients: Ipilimumab or ipilimumab-containing regimens may be offered 1
For BRAF V600-mutant patients: Switch to combination BRAF/MEK inhibitor therapy (dabrafenib plus trametinib, encorafenib plus binimetinib, or vemurafenib plus cobimetinib) 1
After Targeted Therapy Failure
For BRAF V600-mutant patients who progress on BRAF/MEK inhibitors: Switch to anti-PD-1-based immunotherapy as described above 1
Special Populations
Uveal Melanoma
HLA-A*02:01-positive patients with metastatic uveal melanoma should receive tebentafusp (20 mg on day 1,30 mg on day 8, then 68 mg weekly until progression) 1
For HLA-A*02:01-negative uveal melanoma patients, no specific systemic therapy can be recommended; clinical trial enrollment should be prioritized 1
Mucosal Melanoma
The same treatment options recommended for cutaneous melanoma (immunotherapy or targeted therapy for BRAF-mutant disease) should be offered, as these are more likely to be beneficial than KIT-targeted therapy despite nonrandomized data suggesting KIT inhibitor activity 1
Injectable Lesions
For patients with injectable cutaneous, subcutaneous, or nodal unresectable lesions who are not eligible for or decline systemic therapy, talimogene laherparepvec may be offered as primary therapy 1
Emerging Therapies
Lifileucel (Tumor-Infiltrating Lymphocyte Therapy)
Lifileucel received FDA accelerated approval in 2024 for adult patients with unresectable or metastatic melanoma previously treated with anti-PD-1 therapy and (if BRAF V600-mutant) a BRAF inhibitor with or without MEK inhibitor 6
- This is the first FDA-approved tumor-derived T-cell therapy 6
- Objective response rate was 31.5% with median duration of response not reached 6
- Critical warning: Carries a Boxed Warning for treatment-related mortality, prolonged severe cytopenia, severe infection, cardiopulmonary impairment, and renal impairment 6
- 95.5% of patients experienced Grade 3 adverse events and 87.8% experienced Grade 4 adverse events 6
Common Pitfalls to Avoid
- Failing to test for BRAF mutations before initiating therapy limits treatment options and may delay appropriate targeted therapy 7
- Assuming all BRAF mutations are targetable: Only V600E/K mutations have established benefit with BRAF/MEK inhibitors; no recommendation exists for other BRAF mutations 1
- Using targeted therapy in all BRAF-mutant patients without considering clinical factors: This may sacrifice potential long-term survival benefits from immunotherapy in patients who could tolerate delayed response 2, 3
- Overlooking brain metastases management: Both immunotherapy and targeted therapy have intracranial activity, but specific management strategies may be needed 2
Long-Term Outcomes
Ten-year follow-up data demonstrate that both combined CTLA-4/PD-1 inhibition and PD-1 monotherapy can achieve long-term survival in metastatic melanoma 3
Potential surrogate markers for long-term response include: